Compass Therapeutics Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
39
- Stock Symbol
-
CMPX
- Investments
-
2
- Share Price
-
$0.77
- (As of Friday Closing)
Compass Therapeutics General Information
Description
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
Contact Information
Website
www.compasstherapeutics.comCorporate Office
- 80 Guest Street
- Suite 601
- Boston, MA 02135
- United States
Corporate Office
- 80 Guest Street
- Suite 601
- Boston, MA 02135
- United States
Compass Therapeutics Stock Performance
As of 13-Nov-2026, Compass Therapeutics’s stock price is $0.77. Its current market cap is $139M with 180M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.77 | $0.82 | $0.67 - $6.88 | $139M | 180M | 3.89M | -$0.47 |
Compass Therapeutics Financials Summary
As of 30-Sep-2026, Compass Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 17,045 | 745,091 | 70,979 | 37,219 |
| Revenue | 0 | 0 | 850 | 0 |
| EBITDA | (92,616) | (72,589) | (56,075) | (49,694) |
| Net Income | (86,358) | (66,489) | (49,375) | (42,494) |
| Total Assets | 174,498 | 219,588 | 140,403 | 156,875 |
| Total Debt | 9,234 | 9,829 | 6,634 | 1,733 |
Compass Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Compass Therapeutics Comparisons
Industry
Financing
Details
Compass Therapeutics Competitors (92)
One of Compass Therapeutics’s 92 competitors is AnaptysBio, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AnaptysBio | Formerly VC-backed | San Diego, CA | ||||
| Zymeworks | Formerly VC-backed | Vancouver, Canada | ||||
| Arcus Biosciences | Formerly VC-backed | Hayward, CA | ||||
| ProMIS Neurosciences | Corporation | Toronto, Canada | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA |
Compass Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Compass Therapeutics Patents
Compass Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026151679-A1 | Multispecific binding constructs targeting pd-1 and vegf and uses thereof | Pending | 07-Jan-2025 | ||
| WO-2026101896-A1 | Novel prognostic biomarkers in patients with cancer | Pending | 05-Nov-2024 | ||
| AU-2025250196-A1 | Combination of antibodies targeting dll4/vegf and cd137 agonists or anti-pd1/anti-pd-l1 antibodies for the treatment of cancer | Pending | 04-Apr-2024 | ||
| WO-2025212726-A2 | Combination of antibodies targeting dll4/vegf and cd137 agonists or anti-pd1/anti-pd-l1 antibodies for the treatment of cancer | Pending | 04-Apr-2024 | ||
| WO-2025212726-A3 | Combination of antibodies targeting dll4/vegf and cd137 agonists or anti-pd1/anti-pd-l1 antibodies for the treatment of cancer | Pending | 04-Apr-2024 | C07K16/2878 |
Compass Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Compass Therapeutics Acquisitions (2)
Compass Therapeutics’s most recent deal was a Merger/Acquisition with TRIGR Therapeutics for . The deal was made on 25-Jun-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| TRIGR Therapeutics | 25-Jun-2021 | Merger/Acquisition | Drug Discovery | ||
| Olivia Ventures | 23-Jun-2020 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) |
Compass Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
43.51 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Compass Therapeutics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| TRIGR Therapeutics | Irvine, CA | 2018 |
Compass Therapeutics FAQs
-
When was Compass Therapeutics founded?
Compass Therapeutics was founded in 2014.
-
Where is Compass Therapeutics headquartered?
Compass Therapeutics is headquartered in Boston, MA.
-
What is the size of Compass Therapeutics?
Compass Therapeutics has 39 total employees.
-
What industry is Compass Therapeutics in?
Compass Therapeutics’s primary industry is Drug Discovery.
-
Is Compass Therapeutics a private or public company?
Compass Therapeutics is a Public company.
-
What is Compass Therapeutics’s stock symbol?
The ticker symbol for Compass Therapeutics is CMPX.
-
What is the current stock price of Compass Therapeutics?
As of 13-Nov-2026 the stock price of Compass Therapeutics is $0.77.
-
What is the current market cap of Compass Therapeutics?
The current market capitalization of Compass Therapeutics is $139M.
-
Who are Compass Therapeutics’s competitors?
AnaptysBio, Zymeworks, Arcus Biosciences, ProMIS Neurosciences, and CytomX Therapeutics are some of the 92 competitors of Compass Therapeutics.
-
What is Compass Therapeutics’s annual earnings per share (EPS)?
Compass Therapeutics’s EPS for 12 months was -$0.47.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
